Cell Therapy Clinical Trials Dermatology

Targeting Telomeres to Overcome Therapy Resistance in Advanced Melanoma

A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. The research was published in the journal Clinical Cancer Research. The introduction of targeted therapies and immune checkpoint blockade therapies has revolutionized the therapeutic options for patients with advanced melanoma. However, the long-term therapeutic benefit of these new approaches is
Dermatology Gene Therapy

Autologous Cell Therapy for Epidermolysis Bullosa Gains FDA Breakthrough Therapy Designation

Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation status to the Company’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).  The designation from the FDA enables collaborative discussions with senior FDA personnel, priority review and an expedited approval process to drug candidates
Biotechnology cancer Dermatology rare diseases

Cancer therapy shows promise for psoriasis treatment

HDAC inhibitors, already widely used to treat cancer, may be an effective therapy for psoriasis as well, scientists report. They have shown that HDAC3 inhibitors are particularly adept at increasing expression of aquaporin-3, or AQP3, a channel that transports glycerin, a natural alcohol and water attractor, which helps skin look better and aids healthy production and maturation of high-turnover skin cells. "We've found that HDAC3 normally inhibits expression of AQP3
Biotechnology Dermatology

Healing wounds with cell therapy

Diabetic patients frequently have lesions on their feet that are very difficult to heal due to poor blood circulation. In cases of serious non-healing infections, a decision to amputate could be made. A new therapeutic approach, presented recently in the Journal of Investigative Dermatology by Canadian researchers affiliated with the University of Montreal Hospital Research Centre (CRCHUM), could prevent these complications by promoting wound healing. The solution isn't what you
Biotechnology Dermatology

Penn Medicine Launches First Apple ResearchKit App for Sarcoidosis Patients

App combines patient resources with research Penn Medicine today launched its first Apple ResearchKit app, focused on patients with sarcoidosis, an inflammatory condition that can affect the lungs, skin, eyes, heart, brain, and other organs. The effort marks Penn’s first time using modules from Apple’s ResearchKit framework, as part of the institution’s focus on mobile health and innovative research strategies. ResearchKit is an open source software framework designed specifically for
Dermatology

Battling Psoriasis: Can-Fite Advances to Critical Worldwide Phase III Clinical Trial

Psoriasis, a skin disorder expressed by dry, red reptile-like scales, is autoimmune, meaning cells in the body attack cells supposed to help put down the ailment. Several medicines exist, but not without effects that lead to more problems. In what amounts to a psoriasis coup, Can-Fite BioPharma found a way to clear skin and restore quality of life to those with this miserable disease, inciting no adverse consequences, and contained
Dermatology Gene Therapy

Gene therapy for blistering skin disease appears to enhance healing in clinical trial

Grafting sheets of a patient's genetically corrected skin to open wounds caused by the blistering skin disease epidermolysis bullosa appears to be well-tolerated and improves wound healing, according to a phase-1 clinical trial conducted by researchers at the Stanford University School of Medicine. The results mark the first time that skin-based gene therapy has been demonstrated to be safe and effective in patients. The findings will be published Nov. 1